查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861432

虫媒病毒检测市场按检测类型、技术、最终用户、应用和检体类型划分－全球预测（2025-2032 年）

Arbovirus Testing Market by Test Type, Technology, End User, Application, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，虫媒病毒检测市场将成长至 21 亿美元，复合年增长率为 6.02%。

关键市场统计数据
基准年 2024 13.1亿美元
预计年份：2025年 13.9亿美元
预测年份 2032 21亿美元
复合年增长率 (%) 6.02%

在媒介动态变化、临床需求不断演变和监管要求日益提高的背景下，建构现代化的虫媒病毒检测环境

虫媒病毒持续为全球公共卫生系统、诊断实验室和监测机构带来复杂挑战。快速的国际人口迁移、生态系统变化、都市化和气候变迁导致病媒分布和季节性改变，使监测和诊断工作更加复杂。在此背景下，检测技术正在迅速发展，分子平台、免疫检测和照护现场等技术各自满足不同的临床和操作需求。

诊断领域的相关人员面临着一个必须兼顾速度、准确性和扩充性与成本和物流的挑战。实验室被要求将高通量分子检测与血清学确诊检测相结合，而临床医生则需要快速分流工具来指导病患管理决策。研究机构和製药公司正在将诊断策略与疫苗和治疗药物的研发相结合，力求建立能够支持临床试验和上市后监测的检测方法。

此外，日益严格的监管预期和品管框架迫使各机构加强对检验、品管和互通性的投入。这使得平台选择、检体工作流程和供应链韧性等策略决策成为诊断规划的重中之重。本引言旨在透过强调需要技术开发人员、最终使用者和政策制定者共同应对的诸多驱动因素，为更深入的分析奠定基础。

技术创新、数位化连接和灵活的检测流程推动着虫媒病毒诊断领域快速发展的前景

在技​​术创新、数位化整合和营运结构重组的驱动下，虫媒病毒诊断领域正经历变革性的转变。即时PCR和数位PCR等分子检测方法的敏感度和多重检测能力不断提升，能够同时检测多种病原体，并缩短获得有效结果的时间。同时，侧向层析和其他快速诊断方法也在日趋成熟，其灵敏度更高，操作简便，更适合分散式环境。

同时，资料整合和互联互通已成为诊断价值的核心组成部分。实验室资讯系统和云端报告正在促进近实时流行病学监测和更协调的公共卫生应对。这种数位化转型得益于检测设计方面的进步，包括更精确的抗原标靶和改进的单克隆试剂，从而提高了血清学平台的特异性。

另一个显着的变化是，人们越来越重视检体类型的弹性。唾液和尿液等非侵入性检体基质检测表现的提升，正在拓展以地区为基础筛检和儿科族群的检测选择。供应链的考量和成本压力也促使人们更加关注平台整合和模组化工作流程，这些流程能够灵活地在高通量集中检测和照护现场之间切换。总而言之，这些变化正在重塑相关人员对诊断作为综合健康系统应对措施一部分的看法。

评估2025年关税调整对虫媒病毒诊断供应链筹资策略和业务连续性的累积影响

贸易政策和关税调整为虫媒病毒检测所需的试剂、设备和耗材的采购带来了新的考量。 2025年关税调整即时造成了采购的复杂性，迫使各机构重新评估供应商合约、库存策略和跨境物流，以确保检测工作的连续性。某些检测套组组件和设备的额外进口成本也促使各机构更加重视供应链在地化和双重采购安排。

为此，许多实验室和製造商加快了寻找替代供应商的步伐，并加快评估区域性生产合作可行性的工作。这些措施通常涉及调整采购计划，以建立关键试剂的缓衝库存，避免限量供应的药品过时。采购团队越来越多地将关税风险评估纳入供应商选择和合约条款，并就价格保护条款和灵活的交货时间表进行谈判。

此外，受影响地区的监管和海关程序要求与贸易合规专业人员密切合作，以加快关键诊断材料的进口核准。对于参与跨国临床计画的机构而言，这些关税变化也促使其加强与申办者的合作，以确保研究的连续性并防止试剂供应延误。最终，2025年关税的累积影响加速了策略转型，即加强供应链韧性，并促进采购、实验室营运和监管事务部门之间更紧密的合作。

识别测试类型、技术、最终用户、应用和检体类型之间的高价值交叉点，这些交叉点决定了诊断的重要性和策略重点。

細項分析揭示了不同检测类型、技术、最终用户、应用领域和检体基质的性能和应用模式的细微差别，从而提供了诊断需求和机会的多面视角。在检测类型方面，分子检测、快速诊断检测和血清学检测各有侧重，它们各自服务于不同的临床和监测功能，并需要独特的检验途径和操作流程。在技​​术方面，检测方法的开发和部署涉及ELISA、横向流动化验、微阵列平台和PCR技术的选择。在ELISA中，竞争法、间接法和夹心法在灵敏度和交叉反应性方面各有优劣，而侧向层析设计（竞争法和夹心法）则为照护现场应用提供了不同的性能特征。微阵列领域包括DNA微阵列和蛋白质微阵列，它们支持高内涵筛检和病原体发现。 PCR技术包括常规PCR、数位PCR和即时PCR，每种技术都提供不同的分析解析度和通量。在终端使用者层面，诊断需求和采购行为在诊断实验室、医院、製药公司和研究机构之间各不相同。实验室优先考虑检测通量和品管，医院重视快速获得临床结果和易用性，製药公司要求检测方法标准化，而研究机构则专注于创新和发现能力。按应用领域划分，检测方法应用于临床诊断、流行病学监测、研究和兽医检测，这些应用领域影响着性能标准、监管预期和数据报告要求。最后，当根据检体类型进行分类时，样本基质（血浆、唾液、血清、尿液、全血等）会影响检体采集策略、分析前处理和检测灵敏度。样本基质的选择将决定检测的部署地点和方式，从中心实验室到现场。

整合这些细分维度，可以确定哪些领域的投资和创新能带来最大的营运效益。例如，将高灵敏度分子平台与非侵入性检体类型相结合，将扩大社区监测的检测覆盖范围；而优化的血清学ELISA方法在回顾性流行病学调查和疫苗反应监测中仍然至关重要。最终用户的需求表明，没有任何单一技术或检体类型能够占据主导地位，而将技术能力与临床和后勤环境相匹配的混合策略将推动技术的应用和影响力。

检验了美洲、欧洲、中东和非洲以及亚太地区在侦测能力监管和基础设施方面的区域差异对诊断技术应用的影响。

区域趋势对虫媒病毒检测的技术采纳、监管路径和部署策略有显着影响。美洲地区的医疗保健系统多种多样，从高通量集中式实验室到资源有限的社区医疗机构，不一而足，因此对高通量分子平台和可靠的照护现场方案都提出了需求，以支持疫情应对和日常监测。该地区的法规结构也各不相同，一些地区强调加快紧急使用核准流程，而另一些地区则坚持严格的上市前证据要求，这影响了技术的采纳时间和上市后义务。

欧洲、中东和非洲地区（EMEA）的基础设施能力和公共卫生优先事项各不相同。该地区的高所得市场正日益采用先进的分子检测方法和整合数据系统，而资源匮乏的地区则优先采用经济高效的快速诊断方法和能够承受恶劣现场环境的技术。跨境合作和区域公共卫生组织在协调监测方法、安排试剂购买以及协调实验室技术人员培训专案方面发挥着至关重要的作用。

快速的技术应用、对实验室现代化的巨额投资以及不断扩大的本地製造能力，共同创造了亚太地区充满活力的环境。该地区多个国家正在扩展诊断网络，并投资于分散式检查，以加强早期发现和疫情防治。在所有地区，公私合营和国际协作仍然是扩大诊断能力、增强供应链韧性和规范品质保证实践的重要机制。

分析测试开发人员、製造商和供应专家之间的竞争策略和伙伴关係模式：推动采用和营运韧性的因素

产业相关人员正在探索一个竞争格局，在这个格局中，创新、监管合规性和分销能力将决定其影响力和覆盖范围。拥有强大试剂产品组合和检验检测流程的公司正致力于简化监管申报流程并拓展分销网络，以支援跨司法管辖区的部署。检测开发商和仪器製造商之间的策略伙伴关係正在加速「检体到结果」工作流程的整合，从而减少人工操作时间并最大限度地降低人为因素造成的差异。

同时，契约製造和供应专业人员在维持试剂持续供应和满足疫情期间激增的需求方面发挥核心作用。投资于本地生产能力和品管系统的公司能够更好地应对关税相关的干扰，并服务于地域分散的市场。与学术机构和临床中心建立合作关係有助于取得检体库和临床检验途径，对于展现实际应用效果至关重要。

最后，那些将卓越技术与强大的商业策略（灵活的定价模式、培训和支援服务、数据分析解决方案等）相结合的公司将脱颖而出。这些能力将帮助诊断流程中的终端用户，从需要快速整合的医院实验室到寻求高复杂度检测平台的研究机构。

诊断领域的领导企业可以采取切实可行的策略步骤，以提高平台灵活性、确保供应连续性并加速资料驱动的监控能力。

产业领导者应采取一系列协调一致的行动，以加强诊断准备，加速高影响力技术的应用，并降低营运风险。首先，应优先投资于平台互通性和模组化工作流程，使实验室能够在密集型高通量检测和分散式快速诊断之间灵活切换，而无需重复检验。这种方法可以减少营运摩擦，并最大限度地效用现有资源。

接下来，透过对关键试剂的多个供应来源进行资格审核、协商灵活的合约条款以应对前置作业时间波动，以及探索区域製造伙伴关係以缩短交货週期，来规范供应链风险管理。将贸易合规方面的专业知识融入采购和法务部门，可以进一步最大限度地减少海关延误，并确保供应的连续性。

第三，投资数据连接和品质保证基础设施将实现近乎即时的报告，促进机构间数据共用，并支持监控目标的实现。培训和人才培养同样至关重要，旨在提升实验室技术人员和临床医生在新平台上的技能的计划，将在确保数据完整性的同时加速新平台的普及应用。最后，加强与监管机构和公共卫生机构的合作，以简化证据产生流程，并使绩效标准与公共卫生需求保持一致。这些共同努力将加强诊断系统，并提高应对突发疫情和日常监测的准备能力。

我们采用透明的多学科研究方法，结合专家直接参与、技术证据和供应链分析，为我们可操作的诊断见解提供支援。

本分析的调查方法融合了第一手和第二手研究、专家咨询以及多学科检验，以确保其稳健性和相关性。资料来源广泛，包括反映目前检测效能标准和监管要求的各类科学文献、同行评审研究、监管指导文件和技术白皮书。透过与实验室主任、采购负责人、临床研究人员和行业高管的访谈，我们了解了营运实践、推广应用驱动因素和采购限制等相关背景资讯。

在适当情况下，我们整合了实验室检验报告和效能评估，以比较分子、血清学和快速诊断技术的分析特性。供应链分析利用贸易数据、物流案例研究和采购政策审查来评估脆弱性和缓解措施。评估过程中强调了三角验证法，并将定性访谈结果与技术文件和公共卫生报告进行交叉核对，以最大限度地减少偏差，并确保建议的可行性。

在整个研究过程中，我们注意到监管环境以及贸易和关税政策的变化会影响诊断技术的应用。我们也指出了研究的局限性和数据缺口，并将其作为未来进行后续研究或有针对性的基础研究的机会。

整合策略要务和合作途径，以加强诊断系统并提高虫媒病毒检测应对力

总之，虫媒病毒诊断处于技术创新、公共卫生优先事项和营运限制的策略交会点。先进的分子诊断技术、改进的快速诊断方法以及加强的数据协作，为更有效地检测和应对虫媒病毒威胁提供了新的机会。同时，供应链中断和监管复杂性凸显了相关人员之间周密准备和协作的必要性。

因此，决策者应采取混合诊断策略，使技术选择与临床和监测目标一致，促进对供应链韧性的投资，并优先考虑互通性和数据品质。跨部门伙伴关係对于扩大创新规模、协调标准以及确保诊断能力在不同基础设施层级的地区之间公平分配仍然至关重要。协作行动和有针对性的投资可以加强诊断系统，并提供及时可靠的讯息，从而支持临床护理和公共卫生干预措施。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 拓展分子诊断平台，用于快速、多重检测登革热、兹卡病毒、兹卡孔肯雅病毒和其他虫媒病毒，以改善临床决策。
  • 整合数位流行病学和基于 GIS 的监测工具，实现对虫媒病毒疫情的即时监测和资源分配。
  • 引入照护现场核酸检测技术，以便在资源匮乏和偏远的流行地区进行分散式筛检
  • 开发下一代基于 CRISPR 的生物感测器：用于灵敏的照护现场检测虫媒病毒感染疾病
  • 加强公私合营，加速新型黄病毒和甲病毒检测技术的商业化。
  • 具有更高特异性的血清学检测方法，能够区分黄病毒感染疾病中的交叉反应抗体，正变得越来越重要。
  • 引入多重免疫检测试剂盒以提高临床实验室中常见虫媒病毒的鑑别诊断能力

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测类型分類的虫媒病毒检测市场

  • 分子检测
  • 快速诊断测试
  • 血清学检测

9. 按技术分類的虫媒病毒检测市场

  • ELISA
    • 竞争性ELISA
    • 间接ELISA
    • 夹心ELISA
  • 横向流动化验
    • 竞争性试验
    • 夹心法
  • 微阵列
    • DNA微阵列
    • 蛋白质微阵列
  • PCR技术
    • 常规PCR
    • 数位PCR
    • 即时PCR

第十章 依最终用户分類的虫媒病毒检测市场

  • 诊断实验室
  • 医院
  • 製药公司
  • 研究所

第十一章 依应用分類的虫媒病毒检测市场

  • 临床诊断
  • 流行病学监测
  • 研究
  • 兽医检查

12. 依检体类型分類的虫媒病毒检测市场

  • 电浆
  • 唾液
  • 血清
  • 尿
  • 全血

第十三章 各地区虫媒病毒检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 虫媒病毒检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国虫媒病毒检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • QIAGEN NV
    • Hologic, Inc.
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Siemens Healthineers AG
    • PerkinElmer, Inc.
Product Code: MRR-69324464D0E4

The Arbovirus Testing Market is projected to grow by USD 2.10 billion at a CAGR of 6.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.31 billion
Estimated Year [2025] USD 1.39 billion
Forecast Year [2032] USD 2.10 billion
CAGR (%) 6.02%

Framing the modern arbovirus testing environment amid shifting vector dynamics evolving clinical requirements and increasing regulatory expectations

Arboviruses continue to pose complex challenges to public health systems, diagnostic laboratories, and research organizations worldwide. Rapid global travel, shifting ecological patterns, urbanization, and climate variability are contributing to changes in vector distributions and seasonality, which in turn complicate surveillance and diagnosis. Against this backdrop, testing technologies are evolving rapidly, with molecular platforms, immunoassays, and point-of-care diagnostics each responding to distinct clinical and operational demands.

Diagnostic stakeholders are navigating an environment where speed, accuracy, and scalability must be balanced with cost and logistics. Laboratories face pressure to integrate high-throughput molecular testing with confirmatory serological assays, while clinicians require rapid triage tools to inform patient management. Research institutions and pharmaceutical companies are aligning diagnostic strategies with vaccine and therapeutics development, seeking assays that can support clinical trials and post-marketing surveillance.

In addition, regulatory expectations and quality frameworks are tightening, prompting organizations to invest in validation, quality control, and interoperability. Accordingly, strategic decisions around platform selection, sample workflows, and supply chain resilience have moved to the forefront of diagnostic planning. This introduction sets the stage for deeper analysis by highlighting the converging drivers that demand coordinated responses from technology developers, end users, and policy makers.

Navigating a rapidly evolving arbovirus diagnostics landscape propelled by technological advances digital connectivity and flexible testing workflows

The arbovirus diagnostics landscape is undergoing transformative shifts driven by technological innovation, digital integration, and operational reorientation. Molecular methods such as real-time PCR and digital PCR have advanced in sensitivity and multiplexing capability, enabling concurrent detection of multiple pathogens and reducing time to actionable results. At the same time, lateral flow formats and other rapid diagnostics have matured to offer improved sensitivity and user-friendly designs suitable for decentralized settings.

Concurrently, data integration and connectivity have become core components of diagnostic value. Laboratory information systems and cloud-enabled reporting are facilitating near real-time epidemiological surveillance and more coordinated public health responses. This digital transformation is complemented by advances in assay design, including refined antigen targets and improved monoclonal reagents, which have enhanced specificity across serological platforms.

Another notable shift is the emphasis on sample type flexibility. Performance improvements on non-invasive matrices such as saliva and urine are expanding testing options for community-based screening and pediatric populations. Supply chain considerations and cost pressures are also accelerating interest in platform consolidation and modular workflows that can pivot between high-throughput centralized testing and point-of-care deployment. Taken together, these shifts are reshaping how stakeholders conceive of diagnostics as part of integrated health system responses.

Assessing the cumulative repercussions of 2025 tariff adjustments on arbovirus diagnostic supply chains procurement strategies and operational continuity

Trade policies and tariff adjustments have introduced new considerations for sourcing reagents, instruments, and consumables used in arbovirus testing. Tariff changes in 2025 created immediate procurement complexities that required organizations to reassess supplier contracts, inventory strategies, and cross-border logistics to preserve continuity of testing operations. The added import costs on certain assay components and instruments contributed to a renewed focus on supply chain localization and dual-sourcing arrangements.

In response, many laboratories and manufacturers intensified efforts to qualify alternative suppliers and to evaluate the feasibility of regional manufacturing partnerships. These moves were often accompanied by reconfigured purchasing timelines to build buffer stocks for critical reagents while avoiding obsolescence for items with limited shelf life. Procurement teams increasingly incorporated tariff risk assessments into vendor selection and contractual terms, negotiating price protection clauses and flexible delivery schedules.

Moreover, regulatory and customs clearance processes in affected jurisdictions required closer engagement with trade compliance specialists to expedite import approvals for essential diagnostic materials. For organizations involved in multinational clinical programs, these tariff shifts also prompted closer coordination with sponsors to ensure study continuity and to preempt delays in reagent availability. Ultimately, the cumulative impact of the 2025 tariffs accelerated strategic shifts toward supply chain resilience and closer collaboration between procurement, laboratory operations, and regulatory affairs.

Uncovering high-value intersections across test types technologies end users applications and sample types that drive diagnostic relevance and strategic prioritization

Segmentation analysis reveals nuanced performance and adoption patterns across test types, technologies, end users, applications, and sample matrices, providing a multi-dimensional view of diagnostic requirements and opportunities. Based on Test Type, the landscape differentiates between molecular tests, rapid diagnostic tests, and serological tests, each serving discrete clinical and surveillance functions and requiring distinct validation pathways and operational workflows. Based on Technology, assay development and deployment are informed by choices among ELISA, lateral flow assays, microarray platforms, and PCR technologies; within ELISA, competitive, indirect, and sandwich formats present trade-offs in sensitivity and cross-reactivity, while lateral flow designs-competitive assay and sandwich assay-deliver varying performance characteristics for point-of-care use. The microarray domain encompasses both DNA microarray and protein microarray approaches that support high-content screening and pathogen discovery, and PCR technology includes conventional PCR, digital PCR, and real-time PCR, each enabling different analytical resolutions and throughput profiles. Based on End User, diagnostic needs and procurement behaviors differ across diagnostic laboratories, hospitals, pharmaceutical companies, and research institutions, with laboratories prioritizing throughput and quality management, hospitals emphasizing clinical turnaround and ease of use, pharmaceutical companies requiring assay standardization for trials, and research institutions focusing on innovation and exploratory capacity. Based on Application, testing is deployed across clinical diagnostics, epidemiological surveillance, research, and veterinary testing, which shape performance criteria, regulatory expectations, and data reporting requirements. Finally, based on Sample Type, matrices such as plasma, saliva, serum, urine, and whole blood influence specimen collection strategies, pre-analytical handling, and assay sensitivity; the choice of matrix often governs where and how tests are deployed, from centralized labs to field settings.

Integrating these segmentation dimensions suggests where investments and innovations can yield the greatest operational benefits. For example, combining high-sensitivity molecular platforms with non-invasive sample types expands testing reach for community surveillance, whereas optimized serological ELISA formats remain critical for retrospective epidemiology and vaccine response monitoring. End-user needs underscore that no single technology or sample type will dominate; instead, hybrid strategies that match technology capabilities to clinical and logistical contexts will drive adoption and impact.

Examining how regional diversity in capacity regulation and infrastructure among the Americas Europe Middle East & Africa and Asia-Pacific shapes diagnostic deployment

Regional dynamics exert strong influence over technology adoption, regulatory pathways, and deployment strategies for arbovirus testing. In the Americas, health systems vary from high-capacity centralized laboratories to resource-constrained community settings, generating demand for both high-throughput molecular platforms and robust point-of-care solutions that can support outbreak response and routine surveillance. Regulatory frameworks in the region also vary, with some jurisdictions emphasizing rapid emergency use pathways and others maintaining stringent premarket evidence requirements, which affects time to implementation and post-market obligations.

Across Europe, Middle East & Africa, the landscape is characterized by heterogeneity in infrastructural capacity and public health priorities. High-income markets within this region tend to adopt advanced molecular assays and integrated data systems, whereas lower-resource areas prioritize cost-effective rapid diagnostics and technologies that tolerate challenging field conditions. Cross-border cooperation and regional public health bodies play pivotal roles in harmonizing surveillance approaches, facilitating reagent procurement, and coordinating training programs for laboratory personnel.

In Asia-Pacific, rapid technological uptake, significant investments in laboratory modernization, and growing local manufacturing capabilities are shaping a dynamic environment. Several countries in the region are expanding diagnostic networks and investing in decentralized testing to strengthen early detection and outbreak containment. Across all regions, public-private partnerships and international collaborations remain key mechanisms for scaling diagnostic capacity, enhancing supply chain resilience, and standardizing quality assurance practices.

Profiling competitive approaches and partnership models among assay developers manufacturers and supply specialists that drive adoption and operational resilience

Industry participants are navigating a competitive landscape where innovation, regulatory alignment, and distribution capabilities determine influence and reach. Companies with strong reagent portfolios and validated assay pipelines are focusing on streamlining regulatory filings and expanding distribution networks to support multi-jurisdictional deployments. Strategic partnerships between assay developers and instrument manufacturers are accelerating integration of sample-to-answer workflows that reduce hands-on time and minimize user-dependent variability.

At the same time, contract manufacturing and supply specialists are becoming central to maintaining reagent continuity and meeting surge demand during outbreak periods. Firms that invest in local manufacturing capacity and quality management systems are better positioned to respond to tariff-related disruptions and to serve regionally diverse markets. Collaborations with academic and clinical centers facilitate access to specimen panels and clinical validation pathways, which are essential for demonstrating real-world performance.

Finally, companies that combine technical excellence with robust commercial strategies-such as flexible pricing models, training and support services, and data analytics offerings-are differentiating themselves. These capabilities support end users across the diagnostic continuum, from hospital laboratories requiring rapid integration to research institutions seeking high-complexity assay platforms.

Actionable strategic measures for diagnostic leaders to enhance platform flexibility ensure supply continuity and accelerate data driven surveillance capabilities

Industry leaders should pursue a coordinated set of actions to strengthen diagnostic readiness, accelerate adoption of high-impact technologies, and mitigate operational risks. First, prioritize investments in platform interoperability and modular workflows that enable laboratories to pivot between centralized high-throughput testing and decentralized rapid diagnostics without duplicative validation burdens. This approach reduces operational friction and maximizes the utility of existing capital equipment.

Second, formalize supply chain risk management by qualifying multiple sources for critical reagents, negotiating flexible contractual terms to buffer against tariff fluctuations, and exploring regional manufacturing partnerships to shorten lead times. Embedding trade compliance expertise within procurement and legal teams will further minimize customs delays and ensure continuity of supply.

Third, invest in data connectivity and quality assurance infrastructure to enable near real-time reporting, facilitate cross-institutional data sharing, and support surveillance objectives. Training and workforce development are equally essential; targeted programs that upskill laboratory technicians and clinicians in new platforms will accelerate adoption while preserving data integrity. Finally, foster collaborations with regulators and public health agencies to streamline evidence generation and to align performance criteria with public health needs. These combined actions will strengthen diagnostic systems and improve readiness for episodic outbreaks and routine surveillance alike.

Transparent multidisciplinary research approach combining primary expert engagement technical evidence and supply chain analysis to underpin actionable diagnostic insights

The research methodology underpinning this analysis combines primary and secondary evidence, expert consultations, and cross-disciplinary validation to ensure robustness and relevance. Data inputs were collected from a wide range of scientific literature, peer-reviewed studies, regulatory guidance documents, and technical white papers that reflect current assay performance standards and regulatory expectations. Primary interviews with laboratory directors, procurement leads, clinical researchers, and industry executives provided context on operational practices, adoption drivers, and procurement constraints.

Where appropriate, laboratory validation reports and performance evaluations were synthesized to compare analytical characteristics of molecular, serological, and rapid diagnostic technologies. Supply chain analyses drew on trade data, logistics case studies, and procurement policy reviews to assess vulnerabilities and mitigation strategies. The assessment process emphasized triangulation: findings from qualitative interviews were cross-checked against technical documentation and public health reports to minimize bias and to ensure that recommendations are operationally actionable.

Throughout the research, attention was paid to regulatory landscapes and to documented changes in trade and customs policies that influence diagnostic deployment. Limitations and data gaps were identified and flagged for potential follow-up research or targeted primary studies.

Synthesis of strategic imperatives and collaborative pathways to strengthen diagnostic systems and improve arbovirus detection responsiveness

In conclusion, arbovirus diagnostics sit at a strategic intersection of technological innovation, public health priorities, and operational constraints. The convergence of advanced molecular methods, improved rapid diagnostics, and enhanced data connectivity provides new opportunities to detect and respond to arboviral threats more effectively. At the same time, supply chain disruptions and regulatory complexities underscore the need for deliberate planning and cooperative approaches across stakeholders.

Decision-makers should therefore adopt hybrid diagnostic strategies that align technology choice with clinical and surveillance objectives, invest in supply chain resilience, and prioritize interoperability and data quality. Cross-sector partnerships will remain essential to scale innovations, harmonize standards, and ensure that diagnostic capacity is equitably distributed across regions with differing infrastructural capabilities. With coordinated action and targeted investments, diagnostic systems can be strengthened to deliver timely, reliable insights that support clinical care and public health interventions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding molecular diagnostic platforms for rapid multiplex detection of dengue, Zika, chikungunya and other arboviruses to improve clinical decision-making
  • 5.2. Integration of digital epidemiology and GIS-based surveillance tools for real-time arbovirus outbreak monitoring and resource allocation
  • 5.3. Adoption of point-of-care nucleic acid tests enabling decentralised screening in low-resource and remote endemic regions
  • 5.4. Development of next-generation CRISPR-based biosensors for high-sensitivity point-of-care detection of arbovirus infections
  • 5.5. Increasing public-private partnerships to accelerate the commercialization of novel flavivirus and alphavirus testing technologies
  • 5.6. Growing emphasis on serological assays with improved specificity to differentiate cross-reactive antibodies among flavivirus infections
  • 5.7. Implementation of multiplex immunoassay panels that improve differential diagnosis of co-circulating arboviruses in clinical laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Arbovirus Testing Market, by Test Type

  • 8.1. Molecular Tests
  • 8.2. Rapid Diagnostic Tests
  • 8.3. Serological Tests

9. Arbovirus Testing Market, by Technology

  • 9.1. ELISA
    • 9.1.1. Competitive ELISA
    • 9.1.2. Indirect ELISA
    • 9.1.3. Sandwich ELISA
  • 9.2. Lateral Flow Assays
    • 9.2.1. Competitive Assay
    • 9.2.2. Sandwich Assay
  • 9.3. Microarray
    • 9.3.1. DNA Microarray
    • 9.3.2. Protein Microarray
  • 9.4. PCR Technology
    • 9.4.1. Conventional PCR
    • 9.4.2. Digital PCR
    • 9.4.3. Real-Time PCR

10. Arbovirus Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutions

11. Arbovirus Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Epidemiological Surveillance
  • 11.3. Research
  • 11.4. Veterinary Testing

12. Arbovirus Testing Market, by Sample Type

  • 12.1. Plasma
  • 12.2. Saliva
  • 12.3. Serum
  • 12.4. Urine
  • 12.5. Whole Blood

13. Arbovirus Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Arbovirus Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Arbovirus Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. bioMerieux SA
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. Hologic, Inc.
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Danaher Corporation
    • 16.3.9. Siemens Healthineers AG
    • 16.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ARBOVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ARBOVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARBOVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERA